Artal Group’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Artal Group’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$80K	–	155
2022 Q4	$80K	Hold	200,000	–	–	﹤0.01%	128
2022 Q3	$156K	Hold	200,000	–	–	0.01%	133
2022 Q2	$576K	Hold	200,000	–	–	0.03%	120
2022 Q1	$1.25M	Hold	200,000	–	–	0.05%	120
2021 Q4	$2.23M	Hold	200,000	–	–	0.06%	129
2021 Q3	$3.27M	Hold	200,000	–	–	0.07%	125
2021 Q2	$3.71M	Hold	200,000	–	–	0.08%	125
2021 Q1	$3.02M	Buy	+200,000	New	+$4.35M	0.05%	134

Other funds holding CDAK

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artal Group's CDAK Position: Q1 2023 in Review

Artal Group sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 200,000 shares — an estimated $80K sold.

Artal Group first reported a position in CDAK in Q1 2021 and held it in 8 quarters. The position peaked at $3.71M in Q2 2021. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

Artal Group reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Artal Group sold 200,000 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $80K.
Artal Group first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Artal Group's Codiak BioSciences, Inc. Common Stock position peaked at $3.71M in Q2 2021.
27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.